VHAM
UTHR icon

Van Hulzen Asset Management’s United Therapeutics UTHR Stock Holding History

Van Hulzen Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150
Closed -$52.9K – 1071
2024
Q4 		$52.9K Buy
+150
New +$55.1K ﹤0.01% 499

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Van Hulzen Asset Management's UTHR Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 150 shares — an estimated $52.9K sold.

Van Hulzen Asset Management first reported a position in UTHR in Q4 2024 and held it in 1 quarter. The position peaked at $52.9K in Q4 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • Van Hulzen Asset Management reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Van Hulzen Asset Management sold 150 United Therapeutics shares in Q1 2025, an estimated $52.9K.
  • Van Hulzen Asset Management first reported a position in United Therapeutics in Q4 2024 and held it in 1 quarter.
  • Van Hulzen Asset Management's United Therapeutics position peaked at $52.9K in Q4 2024.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.